Article
Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation.
Archives of pathology & laboratory medicine - 1 Jul 2024
Sholl Lynette M, Awad Mark, Basu Roy Upal, Beasley Mary Beth, Cartun Richard Walter, Hwang David M, Kalemkerian Gregory, Lopez-Rios Fernando, Mino-Kenudson Mari, Paintal Ajit, Reid Kearin, Ritterhouse Lauren, Souter Lesley A, Swanson Paul E, Ventura Christina B, Furtado Larissa V
Abstract excerpt
CONTEXT.—: Rapid advancements in the understanding and manipulation of tumor-immune interactions have led to the approval of immune therapies for patients with non-small cell lung cancer. Certain immune checkpoint inhibitor therapies require the use of companion diagnostics, but methodologic variability has led to uncertainty around test selection and implementation in practice. OBJECTIVE.—: To develop...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.